ZYDUSLIFE

Zydus Lifesciences Limited

Global lifesciences company — generics, specialty and complex injectables, from Ahmedabad

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

zyduslife.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-19

Stock price
₹1113.90
Market cap
1,11,167 Cr
Stock P/E
24.6
P/B
4.13
Dividend yield
1.0%
ROE (FY26)
17.0%
ROCE (FY26)
17.3%
Operating margin (FY26)
26.0%
Debt / equity (FY26)
0.43
OCF / EBITDA (FY26)
25.0%
OCF / EBITDA (3Y)
57.9%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

Zydus (Zydus Lifesciences) discovers, makes and sells generic and specialty medicines, biologics, vaccines, consumer wellness products and medical technology products.

Company snapshot

5thBy market cap

Ranked among 119 companies in Pharmaceuticals.

Segment mix

Reportable segments as of 2024-12-31 (Consolidated). Revenue share = segment revenue ÷ total revenue.

Largest segment: 91.3% of revenue

SegmentRevenue shareRevenuePBTAssets
Consumer Products
8.7%
459 Cr9 Cr6,136 Cr
Pharmaceuticals
91.3%
4,810 Cr1,175 Cr26,799 Cr

What we see

Positives
  • ✓Net margin of 18.9% — the business keeps a healthy share of every rupee it earns.
1 more signal from the filings.Sign in free to see them all

Statement tables · Consolidated

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales4,369 Cr4,505 Cr5,534 Cr6,208 Cr5,237 Cr5,269 Cr6,528 Cr6,574 Cr6,123 Cr6,865 Cr7,587 Cr8,017 Cr
Operating expenses (approx.)3,223 Cr3,403 Cr3,903 Cr4,124 Cr3,776 Cr3,882 Cr4,402 Cr4,485 Cr4,107 Cr5,048 Cr5,033 Cr6,088 Cr
EBITDA1,146 Cr1,102 Cr1,631 Cr2,084 Cr1,461 Cr1,388 Cr2,126 Cr2,089 Cr2,016 Cr1,816 Cr2,554 Cr1,929 Cr
OPM %26.2%24.5%29.5%33.6%27.9%26.3%32.6%31.8%32.9%26.5%33.7%24.1%
Other income54 Cr38 Cr156 Cr63 Cr68 Cr58 Cr81 Cr155 Cr109 Cr111 Cr134 Cr106 Cr
Interest9 Cr20 Cr35 Cr32 Cr25 Cr32 Cr77 Cr85 Cr101 Cr130 Cr123 Cr156 Cr
Depreciation184 Cr195 Cr205 Cr215 Cr234 Cr229 Cr238 Cr238 Cr302 Cr360 Cr508 Cr555 Cr
Profit before tax1,029 Cr1,010 Cr1,568 Cr1,919 Cr1,293 Cr1,206 Cr1,667 Cr1,955 Cr1,693 Cr1,411 Cr1,659 Cr1,344 Cr
Tax %22.0%21.8%20.5%22.7%28.9%14.9%25.4%22.2%26.8%27.5%19.2%26.3%
Net profit803 Cr790 Cr1,246 Cr1,483 Cr920 Cr1,026 Cr1,244 Cr1,521 Cr1,239 Cr1,023 Cr1,341 Cr990 Cr
EPS (₹)₹7.91₹7.80₹11.69₹14.11₹9.06₹10.17₹11.64₹14.58₹12.51₹10.36₹12.65₹9.35

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales9,572 Cr11,936 Cr13,166 Cr14,253 Cr15,102 Cr15,265 Cr17,237 Cr19,547 Cr23,242 Cr27,148 CrSign in free for the trailing twelve months
Operating expenses (approx.)7,668 Cr9,089 Cr10,193 Cr11,470 Cr11,761 Cr11,925 Cr13,378 Cr14,163 Cr16,183 Cr18,673 CrSign in free for the trailing twelve months
EBITDA1,904 Cr2,848 Cr2,973 Cr2,783 Cr3,341 Cr3,341 Cr3,860 Cr5,384 Cr7,059 Cr8,475 CrSign in free for the trailing twelve months
OPM %19.9%23.9%22.6%19.5%22.1%21.9%22.4%27.5%30.4%31.2%Sign in free for the trailing twelve months
Other income128 Cr113 Cr201 Cr114 Cr37 Cr225 Cr187 Cr284 Cr270 Cr510 CrSign in free for the trailing twelve months
Interest45 Cr91 Cr194 Cr342 Cr164 Cr127 Cr130 Cr81 Cr166 Cr439 CrSign in free for the trailing twelve months
Depreciation373 Cr539 Cr599 Cr697 Cr725 Cr713 Cr723 Cr764 Cr916 Cr1,408 CrSign in free for the trailing twelve months
Profit before tax1,648 Cr2,375 Cr2,429 Cr1,524 Cr2,332 Cr5,279 Cr2,677 Cr4,957 Cr6,085 Cr6,718 CrSign in free for the trailing twelve months
Tax %7.8%23.8%21.8%21.0%6.3%12.5%21.9%19.8%23.2%23.7%Sign in free for the trailing twelve months
Net profit1,517 Cr1,810 Cr1,899 Cr1,204 Cr2,185 Cr4,618 Cr2,092 Cr3,973 Cr4,673 Cr5,124 CrSign in free for the trailing twelve months
EPS (₹)₹14.53₹17.35₹18.06₹11.49₹20.84₹43.84₹19.30₹38.14₹44.97₹50.09Sign in free for the trailing twelve months
Dividend payout %————0.1%8.1%12.8%15.6%6.5%21.6%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital102 Cr102 Cr102 Cr102 Cr102 Cr102 Cr101 Cr101 Cr101 Cr101 Cr
Reserves6,858 Cr8,642 Cr10,284 Cr10,273 Cr12,890 Cr16,897 Cr17,415 Cr19,729 Cr23,853 Cr27,011 Cr
Borrowings4,945 Cr5,113 Cr7,147 Cr7,041 Cr3,680 Cr4,196 Cr1,163 Cr769 Cr3,170 Cr11,770 Cr
Other liabilities3,159 Cr4,017 Cr4,657 Cr4,935 Cr5,275 Cr4,546 Cr4,905 Cr6,411 Cr7,674 Cr11,055 Cr
Total liabilities15,221 Cr18,065 Cr23,483 Cr23,687 Cr23,885 Cr27,795 Cr25,756 Cr29,281 Cr37,202 Cr52,407 Cr
Fixed assets (net)3,290 Cr3,816 Cr5,106 Cr5,452 Cr5,550 Cr5,762 Cr5,697 Cr5,803 Cr6,042 Cr9,231 Cr
CWIP1,543 Cr1,527 Cr837 Cr742 Cr783 Cr661 Cr1,130 Cr1,112 Cr1,318 Cr1,166 Cr
Investments435 Cr746 Cr674 Cr765 Cr830 Cr3,288 Cr1,547 Cr1,221 Cr6,408 Cr7,540 Cr
Loans & advances——10 Cr0 Cr0 Cr0 Cr0.40 Cr2 Cr77 Cr4 Cr
Inventories1,804 Cr2,385 Cr2,688 Cr2,789 Cr3,236 Cr3,719 Cr3,413 Cr3,442 Cr3,944 Cr5,628 Cr
Trade receivables2,278 Cr3,206 Cr3,951 Cr3,663 Cr3,127 Cr3,340 Cr4,417 Cr5,220 Cr4,025 Cr5,416 Cr
Cash & bank1,544 Cr1,315 Cr421 Cr845 Cr665 Cr658 Cr488 Cr413 Cr827 Cr855 Cr
Other assets4,328 Cr5,070 Cr9,797 Cr9,430 Cr9,693 Cr10,367 Cr9,065 Cr12,069 Cr14,561 Cr22,568 Cr
Total assets15,221 Cr18,065 Cr23,483 Cr23,687 Cr23,885 Cr27,795 Cr25,756 Cr29,281 Cr37,202 Cr52,407 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity1,312 Cr919 Cr1,282 Cr2,505 Cr3,293 Cr2,078 Cr2,689 Cr3,228 Cr6,777 Cr2,117 Cr
Cash from investing-2,872 Cr-974 Cr-4,239 Cr-1,012 Cr-830 Cr1,154 Cr1,171 Cr-1,475 Cr-8,372 Cr-8,296 Cr
Cash from financing2,316 Cr52 Cr1,885 Cr-1,094 Cr-2,549 Cr-868 Cr-4,400 Cr-1,804 Cr2,031 Cr5,997 Cr
Net cash flow756 Cr-3 Cr-1,072 Cr399 Cr-90 Cr2,373 Cr-534 Cr-75 Cr414 Cr28 Cr
Free cash flow (OCF − Capex)-1,628 Cr-130 Cr225 Cr1,601 Cr2,439 Cr876 Cr1,658 Cr2,321 Cr5,064 Cr-1,277 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %14.0%17.6%13.9%10.0%13.4%23.2%13.5%22.0%21.2%17.3%
ROE %20.9%20.3%15.8%10.0%14.3%23.6%10.0%17.5%17.2%17.0%
Debtor days879810994758093976373
Inventory days363340366294303335301274328401
Days payable312269262214207192188169192203
Cash conversion cycle138169213174172222207202199271
OCF / EBITDA %68.9%32.3%43.1%90.0%98.6%62.2%69.7%60.0%96.0%25.0%
OCF / EBITDA % (3 years)——45.5%54.7%77.8%83.2%76.5%63.5%77.9%57.9%
Debt / equity0.710.580.690.680.280.250.070.040.130.43
Current ratio1.141.351.161.051.111.551.812.141.891.27
Net debt / EBITDA1.79—2.262.230.901.060.170.070.331.29